prof-georgina-long

Professor Georgina Long AO

BSc PhD MBBS FRACP FAHMS AAHMS FAA

Medical Director

Professor Georgina Long AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS AAHMS FAA, is Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance.

In recognition of her ground-breaking research and work, Professor Long was named 2024 Australian of the Year and was awarded Fellowship with the Australian Academy of Science (2024), recognized with the Australian Academy of Health and Medical Sciences Outstanding Female Research Medal (2021) and was appointed as an Officer of the Order of Australia (2020). Professor Long has also received numerous awards, including Fulbright U.S. Mission Australia Award for Leadership Excellence (2024), ESMO Women for Oncology Award (2023), Sydney Local Health District/Sydney Research 2022 Research Excellence Award (2022) the prestigious Ramaciotti Medal for Biomedical Research (2021), Vice Chancellor’s Award for Excellence Award for Outstanding Research (2021), University of Sydney (2021), Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including; the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016, 2017, 2018, 2019 & 2020), and in 2013 she was named the Outstanding Cancer Research Fellow.  She is also Clarivate highly-cited Researcher for 2017-2024.  Her H index is 149 and in March 2025 she was ranked the world’s equal 1st melanoma expert in all fields and discipline (https://expertscape.com/ex/melanoma)

Professor Long is the author of over 570 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Journal of Clinical Oncology and Cancer Discovery.  Professor Long has presented her work at international conferences and meetings on more than 300 occasions. She is Past President for the prestigious international Society for Melanoma Research (President 2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020 & 2026 – 2029) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024), Scientific Co-Chair for ESMO Asia (2024) and EADO (2026). She is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

 Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.

Please follow Georgina on social:
Twitter: @ProfGLongMIA
Instagram: @profglong

Contact details 

For all media enquiries, please email media@melanoma.org.au

To make a medical appointment to see Prof Georgina Long AO, or for any clinical concerns, please email smo_reception@melanoma.org.au

To contact Professor Georgina Long AO on all other matters, please email her Executive Assistant, Karen Bush at ealong@melanoma.org.au

Prof Long Recent News

Prof Long Recent Publications

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.

2025-05-29T10:06:37+10:00May 2nd, 2025|Tags: , , , |

Kirkwood JM, Mohr P, Hoeller C, Grob J-J, Del Vecchio M, Lord-Bessen J, Srinivasan S, Nassar A, Campigotto F, Fairbanks H, Taylor F, Lawrance R, Long GV, Weber J. European Journal of Cancer, 220(2025/05/02/ 2025): 115371, doi:https://doi.org/10.1016/j.ejca.2025.115371.

|

Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.

2025-05-29T10:48:41+10:00April 15th, 2025|

Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D. The Lancet Oncology, (Apr 15 2025), doi:10.1016/S1470-2045(25)00139-1.

|

Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort.

2025-05-29T09:54:07+10:00April 14th, 2025|Tags: , , , , , |

Braden J, Potter A, Rawson RV, Adegoke NA, Lo SN, Conway JW, Menzies AM, Carlino MS, Au-Yeung G, Saw RPM, Spillane AJ, Shannon KF, Pennington TE, Ch’ng S, Gyorki DE, Howle JR, Wilmott JS, Scolyer RA, Long GV, Pires da Silva I. Modern Pathology, (Apr 14 2025): 100776, doi:https://doi.org/10.1016/j.modpat.2025.100776. TOP 10%

|

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

2025-05-29T09:59:21+10:00April 8th, 2025|Tags: , , , , |

Grover P, Lo SN, Li I, Kuijpers AMJ, Kreidieh F, Williamson A, Amaral T, Dimitriou F, Placzke J, Olino K, Vitale MG, Saiag P, Gutzmer R, Allayous C, Bagge RO, Mattsson J, Asher N, Carter TJ, Meniawy TM, Lawless AR, Czapla JA, Warburton L, Gaudy-Marquest C, Grob JJ, Collins RG, Zhang E, Kessels JI, Neyns B, Mehmi I, Hamid O, Julve M, Furness AJS, Margolin KA, Levi-Ari S, Ressler JM, Haque W, Khattak MA, Wicky A, Roberts-Thomson R, Arance A, Warrier G, Schollenberger MD, Parente P, Chatziioannou E, Lipson EJ, Michielin O, Weber JS, Hoeller C, Larkin J, Atkins MB, Essner R, Johnson DB, Sullivan RJ, Nathan P, Schachter J, Lebbe C, Ascierto PA, Kluger H, Rutkowski P, Dummer R, Garbe C, Lorigan PC, Burton E, Tawbi HA, Haanen J, Carlino MS, Menzies AM, Long GV. Annals of Oncology, (Apr 08 2025), doi:https://doi.org/10.1016/j.annonc.2025.03.021.

|

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.

2025-05-29T10:21:22+10:00March 23rd, 2025|Tags: , , , , |

Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, Mackiewicz J, Merino LdlC, Chiarion-Sileni V, Kirkwood JM, Robert C, Schadendorf D, de Galitiis F, Carlino MS, Dummer R, Mohr P, Odeleye-Ajakaye A, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. European Journal of Cancer, (Mar 23 2025): 115381, doi:https://doi.org/10.1016/j.ejca.2025.115381.

|

Go to Top